Document:

SCHN EX10.2_2014.11.30-Q1

Exhibit 10.2
Fiscal 2015 Annual Performance Bonus Program
for Tamara L. Lundgren

The Amended and Restated Employment Agreement between the Company and Tamara L. Lundgren provides for an annual cash bonus under a bonus program to be developed by the Compensation Committee (the “Committee”), with bonuses payable based on Company financial performance and achievement of management objectives as determined by the Committee at the beginning of each fiscal year.  The annual bonus program for Ms. Lundgren for fiscal 2015 has two components.  The first component consists of an award with a cash payout based on achievement of Company financial performance targets.  The second component is based on the achievement of management objectives established by the Committee.  The two components of the annual performance bonus program shall operate independently, and the Committee shall make determinations with respect to the second component without regard to the outcomes under the first component.

Company Financial Performance Targets

Calculation of Cash Payout.  For fiscal 2015, the Company financial performance targets shall be the Company’s earnings per share (“EPS”) and return on capital employed (“ROCE”), and each performance target shall be weighted equally.  Cash payouts to the participant under this component of the bonus program shall be determined based on the level of achievement of each performance target.  The Committee has established performance targets for EPS and ROCE and corresponding payouts as a percentage of a participant’s target amount.  Payouts begin at positive levels of EPS and ROCE.

Participant’s Target Amount.  The total target amount for the Company financial performance component shall be 75% of Ms. Lundgren’s annual base salary as in effect on August 31, 2015, with one-half of this target amount subject to each of the two financial performance targets and the maximum total bonus under these two targets not to exceed three times her target amount under this component.  

EPS.  The EPS goal for fiscal 2015 shall be based on the Adjusted EPS for that year.  Adjusted EPS for fiscal 2015 shall mean the Company’s diluted earnings per share for that fiscal year before extraordinary items and the cumulative effects of changes in accounting principles, if any, as set forth in the audited consolidated financial statements of the Company and its subsidiaries for that fiscal year, adjusted to eliminate the impact of such other items as the Committee shall have specified at the time of establishment of the performance targets. 

ROCE.  The ROCE for fiscal 2014 shall be equal to the Company’s Adjusted Operating Income for fiscal 2015 divided by the Company’s Average Capital Employed for fiscal 2015.  Adjusted Operating Income for fiscal 2015 shall mean the Company’s operating income for fiscal 2015 as set forth in the audited consolidated financial statements of the Company and its subsidiaries for fiscal 2015, adjusted to eliminate the impact of such items as the Committee shall have specified at the time of establishment of the performance targets and then reduced by the Company’s forecasted tax rate for fiscal 2015 as set forth in the Company’s Fiscal 2015 Operating Targets document dated 

1

October 29, 2015.  Average Capital Employed for fiscal 2015 shall mean the average of five (5) numbers consisting of the Company’s Capital Employed as of the last day of the fiscal year and as of the last day of the four preceding fiscal quarters.  Capital Employed as of any date shall mean (i) the Company’s total assets (adjusted to eliminate the impact of such items as the Committee shall have specified at the time of establishment of the performance targets), minus (ii) the Company’s total liabilities other than debt for borrowed money and capital lease obligations, in each case as set forth in the consolidated financial statements of the Company and its subsidiaries as of the applicable date or otherwise determined from the Company’s accounting records on a consistent basis.

Change in Accounting Principle.  If the Company implements a change in accounting principle during fiscal 2015 either as a result of issuance of new accounting standards or otherwise, and the effect of the accounting change was not reflected in the Company’s business plan at the time of approval of this award, then EPS and ROCE shall be adjusted to eliminate the impact of the change in accounting principle.

Management Objectives

The second component of the annual bonus program is based on the achievement of the management objectives determined by the Committee.  The Committee shall establish the management objectives and specify the weight to be assigned to each objective.  Following the end of the fiscal year, the Committee shall evaluate Ms. Lundgren’s performance against the management objectives, determine the extent to which each objective has been met and determine the amount of the bonus to be paid.  The target bonus amount for this component of the bonus program shall be 75% of Ms. Lundgren’s annual base salary as in effect on August 31, 2015, and the maximum bonus under this component may not exceed three times her target amount.  The actual amount of the bonus under this component shall be determined by the Committee.

General Provisions

Certification.  Following the end of fiscal 2015 and prior to the payment of any bonus, the Committee shall certify in writing the level of attainment of each performance target for the year and the calculation of the bonus amount.  The bonus payout shall be made in cash as soon as practicable after October 31, 2015 following certification by the Committee.

Conditions to Payment.  Subject to the terms of her employment agreement and change in control agreement, Ms. Lundgren must be employed by the Company on August 31, 2015 to receive the annual bonus.

IRS Section 162(m).  The annual bonus program is implemented pursuant to the Executive Annual Bonus Plan and is intended to qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code.

2OHR PHARMACEUTICAL, INC. 8-K

 

Exhibit 10.50

 

AMENDMENT 1 TO EMPLOYMENT AGREEMENT

This AMENDMENT 1,
dated as of January 6, 2015, to the Employment Agreement (the “Employment Agreement”), dated the 8th day of January,
2014, between OHR PHARMACEUTICAL, INC., a Delaware corporation (the “Company”), and Irach Taraporewala (the “Executive”).

W I T N E S S E T H:

WHEREAS, capitalized
terms not otherwise defined herein shall have the meaning set forth in the Employment Agreement;

NOW, THEREFORE,
in consideration of regulatory requirements and the premises and the agreements hereinafter set forth, the parties hereto agree
as follows:

1.

The Executive and
the Company agree that Section 2 of the Employment Agreement is hereby amended to be and read in its entirety as follows:

“Term
of this Employment Agreement. Subject to Sections 4 and 5 hereof, the Term of this Employment Agreement shall be for the period
of time commencing on January 1, 2015 and continuing until February 28, 2016; provided the Term will automatically renew for successive
one (1) year periods (each, a “Renewal Term”) unless either party delivers written notice of non-renewal to
the other party at least thirty (30) days prior to the expiration of the then-current initial Term or Renewal Term.”

2.

Miscellaneous.
(a)      Except as specifically provided herein, (i) the Employment Agreement shall continue to be in full force and effect and is hereby
in all respects ratified and confirmed, (ii) the execution, delivery and effectiveness of this Amendment 1 shall not operate as
a waiver of any right, power or remedy of the parties under the Employment Agreement, nor constitute a waiver of any provision
of any of the Employment Agreement except as specified herein, (iii) all references to the Employment Agreement in the Employment
Agreement and this Amendment 1 shall refer to the Employment Agreement as amended hereby and as amended from time to time, and
(iv) this Amendment 1 shall be subject to Sections 6 through 10 of the Employment Agreement.

(b)

This Amendment 1
may be executed in any number of counterparts, each of which shall be deemed an original, and all of which shall constitute one
and the same instrument. This Amendment 1 shall be accepted, effective and binding, for all purposes, when the parties shall have
signed and transmitted to each other, by fax, .pdf or otherwise, copies of this Amendment 1.

[Signature Page Follows]

 

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment 1 to Employment Agreement to be duly executed and delivered as of the date and year
first above written.

 

	OHR PHARMACEUTICAL, INC.	 	Executive
	 	 	 	 
	 	 	 	 
	By:	 	 	 
	Name:	 	 	Name: Irach Taraporewala
	Title:OHR PHARMACEUTICAL, INC. 8-K

 

Exhibit 10.51

 

AMENDMENT 1 TO EMPLOYMENT AGREEMENT

This AMENDMENT 1,
dated as of January 6, 2015, to the Employment Agreement (the “Employment Agreement”), dated the 8th day of January,
2014, between OHR PHARMACEUTICAL, INC., a Delaware corporation (the “Company”), and Sam Backenroth (the “Executive”).

W I T N E S S E T H:

WHEREAS, capitalized
terms not otherwise defined herein shall have the meaning set forth in the Employment Agreement;

NOW, THEREFORE,
in consideration of regulatory requirements and the premises and the agreements hereinafter set forth, the parties hereto agree
as follows:

1.

The Executive and
the Company agree that Section 2 of the Employment Agreement is hereby amended to be and read in its entirety as follows:

“Term
of this Employment Agreement. Subject to Sections 4 and 5 hereof, the Term of this Employment Agreement shall be for the period
of time commencing on January 1, 2015 and continuing until February 28, 2016; provided the Term will automatically renew for successive
one (1) year periods (each, a “Renewal Term”) unless either party delivers written notice of non-renewal to
the other party at least thirty (30) days prior to the expiration of the then-current initial Term or Renewal Term.”

2.

Miscellaneous.
(a)      Except as specifically provided herein, (i) the Employment Agreement shall continue to be in full force and effect and is hereby
in all respects ratified and confirmed, (ii) the execution, delivery and effectiveness of this Amendment 1 shall not operate as
a waiver of any right, power or remedy of the parties under the Employment Agreement, nor constitute a waiver of any provision
of any of the Employment Agreement except as specified herein, (iii) all references to the Employment Agreement in the Employment
Agreement and this Amendment 1 shall refer to the Employment Agreement as amended hereby and as amended from time to time, and
(iv) this Amendment 1 shall be subject to Sections 6 through 10 of the Employment Agreement.

(b)

This Amendment 1
may be executed in any number of counterparts, each of which shall be deemed an original, and all of which shall constitute one
and the same instrument. This Amendment 1 shall be accepted, effective and binding, for all purposes, when the parties shall have
signed and transmitted to each other, by fax, .pdf or otherwise, copies of this Amendment 1.

[Signature Page Follows]

 

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment 1 to Employment Agreement to be duly executed and delivered as of the date and year
first above written.

	OHR PHARMACEUTICAL, INC.	 	Executive
	 	 	 	 
	 	 	 	 
	By:	 	 	 
	Name:	 	 	Name: Sam Backenroth
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]